Renal Cell Carcinoma - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 355 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Renal Cell Carcinoma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Renal Cell Carcinoma - Pipeline Review, H2 2014', provides an overview of the Renal Cell Carcinoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Renal Cell Carcinoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Renal Cell Carcinoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Renal Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Renal Cell Carcinoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Renal Cell Carcinoma Overview 10
Therapeutics Development 11
Pipeline Products for Renal Cell Carcinoma - Overview 11
Pipeline Products for Renal Cell Carcinoma - Comparative Analysis 12
Renal Cell Carcinoma - Therapeutics under Development by Companies 13
Renal Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 18
Renal Cell Carcinoma - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Unknown Stage Products 22
Renal Cell Carcinoma - Products under Development by Companies 23
Renal Cell Carcinoma - Products under Investigation by Universities/Institutes 28
Renal Cell Carcinoma - Companies Involved in Therapeutics Development 29
Bristol-Myers Squibb Company 29
Boehringer Ingelheim GmbH 30
F. Hoffmann-La Roche Ltd. 31
Kyowa Hakko Kirin Co., Ltd. 32
Amgen Inc. 33
Eli Lilly and Company 34
GlaxoSmithKline plc 35
MedImmune, LLC 36
Merck & Co., Inc. 37
Celltrion, Inc. 38
Novartis AG 39
ImmunoGen, Inc. 40
Ono Pharmaceutical Co., Ltd. 41
Pfizer Inc. 42
Taiho Pharmaceutical Co., Ltd. 43
Onyx Pharmaceuticals, Inc. 44
Bayer AG 45
Advaxis, Inc. 46
Hemispherx Biopharma, Inc. 47
Celldex Therapeutics, Inc. 48
Aptose Biosciences Inc. 49
Lpath, Inc. 50
Flamel Technologies S.A. 51
Mologen AG 52
Threshold Pharmaceuticals, Inc. 53
Rexahn Pharmaceuticals, Inc. 54
Chipscreen Biosciences Ltd 55
Hutchison MediPharma Limited 56
Cerulean Pharma, Inc. 57
Ambrx, Inc. 58
Boston Biomedical, Inc. 59
Deciphera Pharmaceuticals, LLC 60
Vascular Biogenics Ltd. 61
Advenchen Laboratories, LLC 62
Omeros Corporation 63
Oncolys BioPharma Inc. 64
InteRNA Technologies B.V. 65
Taiwan Liposome Company, Ltd. 66
CureTech Ltd. 67
TRACON Pharmaceuticals, Inc. 68
KAHR medical Ltd. 69
n.v. BRUCELLS s.a. 70
Medical Enzymes AG 71
BiOrion Technologies B.V. 72
SentoClone International AB 73
Ampio Pharmaceuticals, Inc. 74
Karyopharm Therapeutics, Inc. 75
Calithera Biosciences, Inc. 76
Panacela Labs, Inc. 77
Pono Pharma 78
MediaPharma s.r.l. 79
OncoMax 80
SillaJen Co. Ltd. 81
ARMO Biosciences, Inc. 82
Renal Cell Carcinoma - Therapeutics Assessment 82
Assessment by Monotherapy Products 82
Assessment by Combination Products 83
Assessment by Target 84
Assessment by Mechanism of Action 89
Assessment by Route of Administration 94
Assessment by Molecule Type 96
Drug Profiles 99
tivozanib - Drug Profile 99
sorafenib tosylate - Drug Profile 102
axitinib - Drug Profile 106
sunitinib malate - Drug Profile 109
nivolumab - Drug Profile 113
pazopanib hydrochloride - Drug Profile 117
regorafenib - Drug Profile 122
MK-2206 - Drug Profile 124
LT-1009 - Drug Profile 127
carfilzomib - Drug Profile 131
AL-3818 - Drug Profile 134
nintedanib - Drug Profile 136
GlutaDON - Drug Profile 140
pidilizumab - Drug Profile 142
CRLX-101 - Drug Profile 144
TLC-388 - Drug Profile 146
TRC-105 - Drug Profile 148
(tegafur + gimeracil + oteracil) - Drug Profile 150
RG-7446 - Drug Profile 153
HMPL-504 - Drug Profile 154
BBI-503 - Drug Profile 156
RG-7446 + bevacizumab - Drug Profile 157
aldesleukin biobetter - Drug Profile 158
pexastimogene devacirepvec - Drug Profile 159
TH-302 - Drug Profile 161
YN-968D1 - Drug Profile 168
OncoVAX - Drug Profile 171
Cell Therapy for Renal Cell Carcinoma - Drug Profile 173
Cell Therapy for Oncology and Infectious Disease - Drug Profile 174
MGN-1601 - Drug Profile 175
emibetuzumab - Drug Profile 177
pembrolizumab - Drug Profile 178
afuresertib hydrochloride + trametinib dimethyl sulfoxide - Drug Profile 180
Allogeneic Dendritic Cell Cancer Vaccine - Drug Profile 182
pazopanib hydrochloride + pembrolizumab - Drug Profile 184
MDX-1203 - Drug Profile 185
varlilumab - Drug Profile 186
pexastimogene devacirepvec - Drug Profile 188
rintatolimod - Drug Profile 190
SF-1126 - Drug Profile 192
VB-111 - Drug Profile 194
DMS-612 - Drug Profile 195
CS-2164 - Drug Profile 196
SentoClone - Drug Profile 197
MDX-1411 - Drug Profile 199
BYL-719 - Drug Profile 200
X-82 - Drug Profile 201
IMGN-853 - Drug Profile 202
AMG-172 - Drug Profile 204
MEDI-0680 - Drug Profile 206
CB-839 - Drug Profile 207
AM-0010 - Drug Profile 208
DNA Vaccine to Target Prostate Specific Membrane Antigen for Renal Cell Carcinoma - Drug Profile 209
MDNA-55 - Drug Profile 210
LOR-1284 - Drug Profile 211
RX-3117 - Drug Profile 212
CDX-014 - Drug Profile 213
OBP-801 - Drug Profile 214
KAHR-101 - Drug Profile 215
bevacizumab biosimilar - Drug Profile 216
BCL-004 - Drug Profile 217
AL-8326 - Drug Profile 218
MVAME-03 - Drug Profile 219
AL-2846 - Drug Profile 220
NCE-001 - Drug Profile 221
MicroRNA for GBM and Renal Cell cancer - Drug Profile 222
CYP-0150 - Drug Profile 224
BC-2059 - Drug Profile 225
Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - Drug Profile 226
BOT-161 - Drug Profile 227
BOT-191 - Drug Profile 228
Small Molecule to Target GPR65 for Cancer and Inflammatory Disorders - Drug Profile 229
OMRCA-01 - Drug Profile 230
KPT-251 - Drug Profile 232
Protein for Renal Cell Carcinoma - Drug Profile 233
Lm-LLO-HMWMAAC - Drug Profile 234
DCC-3014 - Drug Profile 236
Lm-LLO-CA9 - Drug Profile 237
MPHE-001B - Drug Profile 239
Monoclonal Antibody Drug Conjugate to Inhibit CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma - Drug Profile 240
STF-31 - Drug Profile 241
STF-62247 - Drug Profile 242
tetraiodothyroacetic acid nanoparticle - Drug Profile 243
SRX-2523 - Drug Profile 244
Small Molecules to Activate AMPK for Renal Cell Carcinoma - Drug Profile 245
Syrbactins - Drug Profile 246
Oncolipin-IV - Drug Profile 247
Renal Cell Carcinoma - Recent Pipeline Updates 248
Renal Cell Carcinoma - Dormant Projects 334
Renal Cell Carcinoma - Discontinued Products 336
Renal Cell Carcinoma - Product Development Milestones 337
Featured News & Press Releases 337
Appendix 348
Methodology 348
Coverage 348
Secondary Research 348
Primary Research 348
Expert Panel Validation 348
Contact Us 349
Disclaimer 349

List of Tables
Number of Products under Development for Renal Cell Carcinoma, H2 2014 17
Number of Products under Development for Renal Cell Carcinoma - Comparative Analysis, H2 2014 18
Number of Products under Development by Companies, H2 2014 20
Number of Products under Development by Companies, H2 2014 (Contd..1) 21
Number of Products under Development by Companies, H2 2014 (Contd..2) 22
Number of Products under Development by Companies, H2 2014 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H2 2014 24
Comparative Analysis by Late Stage Development, H2 2014 25
Comparative Analysis by Clinical Stage Development, H2 2014 26
Comparative Analysis by Early Stage Development, H2 2014 27
Comparative Analysis by Unknown Stage Development, H2 2014 28
Products under Development by Companies, H2 2014 29
Products under Development by Companies, H2 2014 (Contd..1) 30
Products under Development by Companies, H2 2014 (Contd..2) 31
Products under Development by Companies, H2 2014 (Contd..3) 32
Products under Development by Companies, H2 2014 (Contd..4) 33
Products under Investigation by Universities/Institutes, H2 2014 34
Renal Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H2 2014 35
Renal Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2014 36
Renal Cell Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 37
Renal Cell Carcinoma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 38
Renal Cell Carcinoma - Pipeline by Amgen Inc., H2 2014 39
Renal Cell Carcinoma - Pipeline by Eli Lilly and Company, H2 2014 40
Renal Cell Carcinoma - Pipeline by GlaxoSmithKline plc, H2 2014 41
Renal Cell Carcinoma - Pipeline by MedImmune, LLC, H2 2014 42
Renal Cell Carcinoma - Pipeline by Merck & Co., Inc., H2 2014 43
Renal Cell Carcinoma - Pipeline by Celltrion, Inc., H2 2014 44
Renal Cell Carcinoma - Pipeline by Novartis AG, H2 2014 45
Renal Cell Carcinoma - Pipeline by ImmunoGen, Inc., H2 2014 46
Renal Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 47
Renal Cell Carcinoma - Pipeline by Pfizer Inc., H2 2014 48
Renal Cell Carcinoma - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2014 49
Renal Cell Carcinoma - Pipeline by Onyx Pharmaceuticals, Inc., H2 2014 50
Renal Cell Carcinoma - Pipeline by Bayer AG, H2 2014 51
Renal Cell Carcinoma - Pipeline by Advaxis, Inc., H2 2014 52
Renal Cell Carcinoma - Pipeline by Hemispherx Biopharma, Inc., H2 2014 53
Renal Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H2 2014 54
Renal Cell Carcinoma - Pipeline by Aptose Biosciences Inc., H2 2014 55
Renal Cell Carcinoma - Pipeline by Lpath, Inc., H2 2014 56
Renal Cell Carcinoma - Pipeline by Flamel Technologies S.A., H2 2014 57
Renal Cell Carcinoma - Pipeline by Mologen AG., H2 2014 58
Renal Cell Carcinoma - Pipeline by Threshold Pharmaceuticals, Inc., H2 2014 59
Renal Cell Carcinoma - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2014 60
Renal Cell Carcinoma - Pipeline by Chipscreen Biosciences Ltd, H2 2014 61
Renal Cell Carcinoma - Pipeline by Hutchison MediPharma Limited, H2 2014 62
Renal Cell Carcinoma - Pipeline by Cerulean Pharma, Inc., H2 2014 63
Renal Cell Carcinoma - Pipeline by Ambrx, Inc., H2 2014 64
Renal Cell Carcinoma - Pipeline by Boston Biomedical, Inc., H2 2014 65
Renal Cell Carcinoma - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2014 66
Renal Cell Carcinoma - Pipeline by Vascular Biogenics Ltd., H2 2014 67
Renal Cell Carcinoma - Pipeline by Advenchen Laboratories, LLC, H2 2014 68
Renal Cell Carcinoma - Pipeline by Omeros Corporation, H2 2014 69
Renal Cell Carcinoma - Pipeline by Oncolys BioPharma Inc., H2 2014 70
Renal Cell Carcinoma - Pipeline by InteRNA Technologies B.V., H2 2014 71
Renal Cell Carcinoma - Pipeline by Taiwan Liposome Company, Ltd., H2 2014 72
Renal Cell Carcinoma - Pipeline by CureTech Ltd., H2 2014 73
Renal Cell Carcinoma - Pipeline by TRACON Pharmaceuticals, Inc., H2 2014 74
Renal Cell Carcinoma - Pipeline by KAHR medical Ltd., H2 2014 75
Renal Cell Carcinoma - Pipeline by n.v. BRUCELLS s.a., H2 2014 76
Renal Cell Carcinoma - Pipeline by Medical Enzymes AG, H2 2014 77
Renal Cell Carcinoma - Pipeline by BiOrion Technologies B.V., H2 2014 78
Renal Cell Carcinoma - Pipeline by SentoClone International AB, H2 2014 79
Renal Cell Carcinoma - Pipeline by Ampio Pharmaceuticals, Inc., H2 2014 80
Renal Cell Carcinoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 81
Renal Cell Carcinoma - Pipeline by Calithera Biosciences, Inc., H2 2014 82
Renal Cell Carcinoma - Pipeline by Panacela Labs, Inc., H2 2014 83
Renal Cell Carcinoma - Pipeline by Pono Pharma, H2 2014 84
Renal Cell Carcinoma - Pipeline by MediaPharma s.r.l., H2 2014 85
Renal Cell Carcinoma - Pipeline by OncoMax, H2 2014 86
Renal Cell Carcinoma - Pipeline by SillaJen Co. Ltd., H2 2014 87
Assessment by Monotherapy Products, H2 2014 88
Assessment by Combination Products, H2 2014 89
Number of Products by Stage and Target, H2 2014 92
Number of Products by Stage and Mechanism of Action, H2 2014 97
Number of Products by Stage and Route of Administration, H2 2014 101
Number of Products by Stage and Molecule Type, H2 2014 104
Renal Cell Carcinoma Therapeutics - Recent Pipeline Updates, H2 2014 254
Renal Cell Carcinoma - Dormant Projects, H2 2014 340
Renal Cell Carcinoma - Discontinued Products, H2 2014 342